Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers

Healthy Subjects Clinical Trial

Official title:

A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of VV116 After Multiple Ascending Doses Administered Orally to Chinese Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05201690
• Other study ID #: VV116-02
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2021
• Est. completion date: January 23, 2022

Study information

• Verified date: December 2021
• Source: Vigonvita Life Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blinded, placebo-controlled, single-center phase I clinical trial. The objective of this study is to evaluate the safety, tolerability, pharmacokinetic profiles of VV116 tablets after multiple ascending doses administered orally to Chinese healthy volunteers.

Description:

Multiple-dose ascending design is used in the trial, VV116/Placebo is administered sequentially from low-dose to high-dose and each subject can only orally receive one dose level. There are 3 dose groups (200mg, 400mg, 600mg), investigational product is orally administrated BID for 5.5 days, the last dose is taken in D6 morning. When 7th day visit after last dose (D12) is completed for previous dose group, investigator and sponsor will evaluate the safety and determine whether the next dose group can be started. 12 subjects will be enrolled in each dose group and the ratio of investigational product to placebo is 3:1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: January 23, 2022
• Est. primary completion date: January 19, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy subjects between the ages of 18 and 45 years;

2. Body weight no less than 50 kg for male, no less than 45 kg for female; Body Mass Index of 19 to 26kg/m2;

3. Physical examination, vital signs examination, laboratory examination, ECG, B-ultrasound and fundus examination results were normal or abnormal without clinical significant;

4. Subjects who are willing to take proper contraceptive during the study and within 3 months after the study completed;

5. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the informed consent form;

Exclusion Criteria:

1. Subjects with hypersensitivity to VV116 or any of the excipients;

2. Subjects with allergic diseases or allergic constitution;

3. Subjects with central nervous system,cardiovascular system,gastrointestinal, respiratory system,urinary,Hematologic System,metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;

4. Blood donation or blood loss = 400 mL within 3 months prior to inclusion, or have a history of blood product use history;

5. Participated in a clinical study involving another investigational drug within 3 month before the screening visit;

6. Taken any prescription drugs, non-prescription drugs, Chinese herbal medicine or health care products within 2 weeks prior to screening;

7. Drug or alcohol addicts within 1 year prior to screening, who drink at least twice a day or more than 14 units per week, or who are addicted to alcohol (1 unit ˜200 mL beer with 5% alcohol content, 25 mL spirits with 40% alcohol content or 85 mL wine with 12% alcohol content) ;

8. Those who smoke more than 10 cigarettes per day and do not agree to avoid using any tobacco products during the trial period;

9. Those who cannot quit smoking or drinking during the trial;

10. Those who are positive for hepatitis B surface antigen (HBsAg), HCV antibody, syphilis antibody and HIV antibody;

11. Abnormal and clinically significant chest radiographs (anteroposterior);

12. B ultrasound examination showed moderate to severe fatty liver;

13. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeded the upper normal limit (ULN) at screening time or baseline;

14. Glomerular filtration rate (eGFR) < 90 mL/min/1.73m2 at screening time or baseline;

15. Abnormal ecg at screening or baseline, single QTcF (corrected for heart rate) > 450 ms in men, > 470 ms in women, and/or other clinically significant abnormalities;

16. Pregnant or lactating women or male subjects whose spouse has a child care plan within 3 months;

17. The investigator believes that there are other factors that are not suitable for participating in this trial.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• VV116 200 mg Group
Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
• VV116 400mg Group
Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
• VV116 600mg Group
Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;

Locations

Country	Name	City	State
China	Shanghai Xuhui Central Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Vigonvita Life Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment emergent treatment-related adverse event(s)	Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs	Dosing through follow-up call (7 days after last dose of investigational product)
Primary	Number of participants with laboratory test findings of potential clinical importance		Dosing through follow-up call (7 days after last dose of investigational product)
Primary	Number of participants with vital signs findings of potential clinical importance		Dosing through follow-up call (7 days after last dose of investigational product)
Primary	Number of participants with ECG findings of potential clinical importance	Number of subjects with change from baseline in electrocardiogram (ECG) parameters	Dosing through follow-up call (7 days after last dose of investigational product)
Secondary	Tmax	Time to reach maximum observed plasma concentration	Calculated using concentration data collected from predose to 48 hours postdose
Secondary	Cmax	Maximum observed plasma concentration	Calculated using concentration data collected from predose to 48 hours postdose
Secondary	T1/2	Terminal half life	Calculated using concentration data collected from predose to 48 hours postdose
Secondary	AUC0-T	Calculated using concentration data collected from predose to 48 hours postdose	Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration.
Secondary	AUC0-8	Area under the plasma concentration-time curve from time 0 extrapolated to infinity	Calculated using concentration data collected from predose to 48 hours postdose